RedDress is the developer of ActiGraft, an FDA-cleared regenerative wound care solution based on the companys proprietary patented technology for reproducing the bodys natural ability to heal wounds.
ActiGraft enables healthcare providers to produce, in real-time, in vitro blood clots from a patients whole blood. Once applied, the blood clots serve as a protective covering, biologic scaffold, and wound microenvironment to help promote the bodys natural wound-healing processes.
Cumulative Funding Raised Over Time ($)
Employees Over Time
RedDress Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Jul 18, 2023
www.themarker.com
"זה החלום של כל חברה רפואית": מדיקר תממן את הטיפול של רדדרס הישראלית
#Customers #Partners
Jul 18, 2023
www.prnewswire.com
RedDress Launches ActiGraft PRO with G-Code Reimbursement Status for the US Wound Care Market
#Customers, Expand
May 24, 2023
www.prnewswire.com
RedDress Raises $26 Million to Give Patients the Power to Heal Chronic Wounds Using Their Own Blood
#Investment
Jan 20, 2023
www.globenewswire.com
RedDress Announces Positive Results Specifying Use on Complex Wounds
#Customers
Oct 4, 2022
www.globenewswire.com
RedDress Receives Vizient Innovative Technology Contract for ActiGraft® systems